Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal Oxytocin for Methamphetamine Withdrawal in Women
NCT05760807Completed
- Sponsor
- Turning Point Therapeutics, Inc.
- Start
- Mar 2023
- Primary completion
- Mar 2024
- Countries
- 1
01
Overview
Open-label, single-arm trial of oxytocin nasal spray in methamphetamine use disorder (MUD), sponsored by Turning Point Therapeutics, Inc. Primary endpoint: Feasibility assessment. Started Mar 2023; status: completed.
02
Drugs
oxytocin nasal spray
03
Conditions
methamphetamine use disorder (MUD)
Beyond the preview
Go deeper on NCT05760807.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05760807.